Russia's Protek closes IPO
This article was originally published in Scrip
Executive Summary
One of Russia's largest pharmaceutical companies, Protek, has completed its IPO, having priced it at $3.50 per ordinary share, which gave it a market capitalisation of $1.8 billion. It has become the second public pharmaceutical company in Russia after Pharmstandard.